Chronic thromboembolic pulmonary hypertension after pulmonary embolism

Predictors for Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism Episode

This project tests how often people who had an acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension (CTEPH) and which symptoms and echocardiography findings predict it in symptomatic patients.

Quick facts

• Study type: Observational
• Enrollment: 100 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Assiut University (Academic / other)
• Locations: 1 site (Asyut)
• Trial ID: NCT06081881 on ClinicalTrials.gov

What this trial studies

This is an observational cohort of adults with recent acute pulmonary embolism who meet higher-risk PESI/sPESI criteria, followed to detect incident CTEPH. Participants undergo baseline clinical evaluation and transthoracic Doppler echocardiography with attention to RV function and specific Doppler signs, and are followed for imaging or clinical confirmation of CTEPH. Patients with secondary causes of pulmonary hypertension, severe renal or hepatic impairment, or contraindications to anticoagulation are excluded. The primary goal is to predict CTEPH occurrence in symptomatic post-PE patients using clinical and echocardiographic markers.

Who should consider this trial

Good fit: Adults aged 18–80 with a recent acute pulmonary embolism and higher risk by PESI class III–V or sPESI ≥1 who have persistent symptoms are the intended participants.

Not a fit: Patients with known secondary causes of pulmonary hypertension, severe kidney or liver impairment, or contraindications to anticoagulation are unlikely to benefit or be eligible for this protocol.

Why it matters

Potential benefit: If successful, earlier identification of patients at risk for CTEPH could enable timely referral for potentially curative treatments and reduce long-term disability.

How similar studies have performed: Previous observational cohorts have estimated CTEPH incidence after PE and identified echocardiographic and clinical risk factors, so this approach builds on existing, but still limited, evidence.

Eligibility criteria

Inclusion Criteria:

Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1,

Exclusion Criteria:

Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation

Where this trial is running

Asyut

• Assiut University — Asyut, Egypt (Recruiting)

Study contacts

• Principal investigator: Ester A Faried, Resident — Assiut University
• Study coordinator: Ester A Faried, resident

Conditions Chronic Thromboembolic Pulmonary Hypertension; CTEPH